Oprozomib
Code | Size | Price |
---|
TAR-T6041-1mg | 1mg | £118.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6041-5mg | 5mg | £176.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6041-1mL | 1 mL * 10 mM (in DMSO) | £193.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6041-10mg | 10mg | £211.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6041-25mg | 25mg | £321.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6041-50mg | 50mg | £446.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Oprozomib (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5?IC50=36 nM?/LMP7?IC50=82 nM?, is orally bioavailable. Oprozomib also has potential antineoplastic activity.
CAS:
935888-69-0
Formula:
C25H32N4O7S
Molecular Weight:
532.61
Pathway:
Autophagy; Ubiquitination; Proteases/Proteasome
Purity:
0.9987
SMILES:
s1c(ncc1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@@]1(OC1)C)Cc1ccccc1)COC)COC)C
Target:
Proteasome; Autophagy
References
Chen X, Chen Y, Ou Y, et al. Bortezomib inhibits NLRP3 inflammasome activation and NF-?B pathway to reduce psoriatic inflammation. Biochemical Pharmacology. 2022, 206: 115326.
Chauhan D, et al. Blood, 2010, 116(23), 4906-4915.
Muchamuel T, Nat Med, 2009, 15(7), 781-787.
Chen X, Chen Y, Ou Y, et al. Bortezomib inhibits NLRP3 inflammasome activation and NF-?B pathway to reduce psoriatic inflammation. Biochemical Pharmacology. 2022, 206: 115326.
Zhou HJ, et al. J Med Chem, 2009, 52(9), 3028-3038.